CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., today announced that results from in-vivo preclinical studies with the Company’s ghrelin agonist, EX-1314, were presented at the annual meeting of the Endocrine Society. EX-1314 is expected to enter human clinical testing this year. This new compound has been the subject of extensive preclinical development, and these new data provide the first demonstrations that an orally active, small molecule ghrelin agonist can enhance gastrointestinal motility. Elixir will develop EX-1314 as a treatment for gastrointestinal disorders, which include gastroparesis, opioid-induced bowel dysfunction and cancer cachexia. These newest findings were presented in a poster session, titled “Enhanced gastrointestinal motility with EX-1314, an orally active small molecule ghrelin receptor agonist,” at ENDO 2008, the annual meeting of the Endocrine Society being held in San Francisco. Authors of the study included Soratree Charoenthongtrakul and Brad Geddes, both of Elixir Pharmaceuticals.
